DeepMed Research

Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

Phase 1

Completed

Conditions: Corneal Endothelial Cell Changes

Interventions: Drug: Mapracorat

First Posted Date: 2012-11-29

Last Posted Date: 2013-11-26

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 61

Registration Number: NCT01736462

Locations: 🇺🇸
Bausch & Lomb Inc, Rochester, New York, United States

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: LE Gel

First Posted Date: 2012-11-29

Last Posted Date: 2013-11-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 12

Registration Number: NCT01736527

Locations: 🇺🇸
Bausch & Lomb Research Clinic, Rochester, New York, United States

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Phase 3

Completed

Conditions: Open Angle or Ocular Hypertension
Glaucoma

Interventions: Drug: Azopt 1%
Drug: brinzolamide 1% ophthalmic suspension

First Posted Date: 2012-11-07

Last Posted Date: 2023-05-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 258

Registration Number: NCT01722604

Locations: 🇺🇸
US01, Louisville, Kentucky, United States

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Ocular Hypertension
Open Angle Glaucoma

Interventions: Drug: BOL-303259-X
Drug: Timolol maleate

First Posted Date: 2012-10-16

Last Posted Date: 2018-09-04

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 25

Registration Number: NCT01707381

Locations: 🇺🇸
University of California San Diego, La Jolla, California, United States

Evaluation of Ocular Comfort With ISTA Tears vs Systane

Not Applicable

Completed

Conditions: Dry Eye Disease

Interventions: Drug: ISTA Tears
Drug: Systane

First Posted Date: 2012-07-26

Last Posted Date: 2024-10-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 35

Registration Number: NCT01650584

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: IOL Implantation

First Posted Date: 2012-06-11

Last Posted Date: 2019-11-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 103

Registration Number: NCT01615861

Locations: 🇫🇷
Bausch & Lomb, Labege, France

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3

Completed

Conditions: Surgery
Inflammation
Cataract

Interventions: Drug: Vehicle
Drug: Mapracorat

First Posted Date: 2012-05-04

Last Posted Date: 2020-09-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 360

Registration Number: NCT01591655

Locations: 🇺🇸
Bausch & Lomb, Incorporated, Rochester, New York, United States

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3

Completed

Conditions: Cataract
Inflammation
Surgery

Interventions: Drug: Placebo
Drug: Mapracorat

First Posted Date: 2012-05-03

Last Posted Date: 2020-09-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 369

Registration Number: NCT01591161

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contact Lenses

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: PureVision2
Device: B&L RD2135-01 lens C
Device: Air Optix Aqua
Device: B&L RD2135-01 lens D

First Posted Date: 2012-04-24

Last Posted Date: 2020-10-22

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 216

Registration Number: NCT01583868

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Bepotastine besilate formulation
Drug: Fluticasone propionate
Drug: Bepotastine besilate-fluticasone propionate
Drug: Placebo Comparator

First Posted Date: 2012-04-16

Last Posted Date: 2020-10-05

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 606

Registration Number: NCT01578278

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy